Home » Stocks » EYEN

Eyenovia, Inc. (EYEN)

Stock Price: $6.56 USD -0.01 (-0.15%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.13 -0.43 (-6.56%) Jan 15, 7:07 PM
Market Cap 163.99M
Revenue (ttm) n/a
Net Income (ttm) -20.80M
Shares Out 22.21M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.56
Previous Close $6.57
Change ($) -0.01
Change (%) -0.15%
Day's Open 6.45
Day's Range 6.33 - 6.89
Day's Volume 118,350
52-Week Range 1.77 - 6.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a mark...

Business Wire - 2 weeks ago

NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.

Business Wire - 4 weeks ago

NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)-- #Eyenovia--Eyenovia obtains FDA acceptance of its IND application for MicroLine, a therapy designed for improvement in near vision in patients with presbyopia.

Seeking Alpha - 2 months ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

Zacks Investment Research - 3 months ago

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

Other stocks mentioned: BHC
GlobeNewsWire - 3 months ago

Company reaffirms near term milestones for the Mydcombi™ (MicroStat) NDA and the MicroLine presbyopia program Phase III results

Seeking Alpha - 3 months ago

One year ago, I recommended Eyenovia's stock based on the company's effort in addressing several ophthalmic needs. Since that time, the stock has stagnated yet two collaborations have been ann...

PRNewsWire - 3 months ago

LAVAL, QC and NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc.,...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)-- #AAOPT--Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

GlobeNewsWire - 4 months ago

NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

Seeking Alpha - 5 months ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2020 Results - Earnings Call Transcript

InvestorPlace - 5 months ago

Eyenovia (EYEN) is in the news Tuesday after an exclusive deal with Arctic Vision for two of its treatments sent EYEN stock soaring higher. The post Eyenovia News: Why EYEN Stock Is Skyrocketi...

24/7 Wall Street - 5 months ago

Eyenovia Inc. (NASDAQ: EYEN) shares soared on Tuesday after the company announced an exclusive license agreement with Artic Vision to develop and commercialize its MicroPine for the treatment ...

GlobeNewsWire - 5 months ago

NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

GlobeNewsWire - 6 months ago

NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therape...

GlobeNewsWire - 7 months ago

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...

GlobeNewsWire - 7 months ago

NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...

Seeking Alpha - 8 months ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Eyenovia

Seeking Alpha - 9 months ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...

GlobeNewsWire - 9 months ago

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing it...

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).

Zacks Investment Research - 1 year ago

Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Seeking Alpha - 1 year ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Other stocks mentioned: ACIU, ASND, NGM, SAGE
GlobeNewsWire - 1 year ago

Defers development activities of MicroProst and MicroTears

Seeking Alpha - 1 year ago

Eyenovia is a specialty ophthalmic company targeting several ophthalmic needs, including progressive myopia and presbyopia.

GlobeNewsWire - 1 year ago

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing it...

Seeking Alpha - 1 year ago

Today, we take an in-depth look at a microcap 'Busted IPO' named Eyenovia.

Seeking Alpha - 1 year ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2019 - Earnings Call Transcript

GuruFocus - 1 year ago

CEO of Eyenovia Inc (30-Year Financial, Insider Trades) Tsontcho Ianchulev (insider trades) bought 233,813 shares of EYEN on 07/11/2019 at an average price of $2.78 a share.

Seeking Alpha - 1 year ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2018 Results - Earnings Call Transcript

About EYEN

Eyenovia, a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, throug... [Read more...]

Industry
Biotechnology
IPO Date
Jan 25, 2018
CEO
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
EYEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Eyenovia stock is "Buy." The 12-month stock price forecast is 12.00, which is an increase of 82.93% from the latest price.

Price Target
$12.00
(82.93% upside)
Analyst Consensus: Buy